Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages
Shuai Xia, Lijue Wang, Yun Zhu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 134

Showing 1-25 of 134 citing articles:

Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2
Panke Qu, John P. Evans, Julia N. Faraone, et al.
Cell Host & Microbe (2022) Vol. 31, Iss. 1, pp. 9-17.e3
Open Access | Times Cited: 236
Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2
Panke Qu, John P. Evans, Julia N. Faraone, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 80
Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
Alexander Muik, Bonny Gaby Lui, Maren Bacher, et al.
Science Immunology (2022) Vol. 7, Iss. 77
Open Access | Times Cited: 68
COVID‐19 in early 2023: Structure, replication mechanism, variants of SARS‐CoV‐2, diagnostic tests, and vaccine & drug development studies
İlker Polatoğlu, Tülay Öncü Öner, Irem Dalman, et al.
MedComm (2023) Vol. 4, Iss. 2
Open Access | Times Cited: 43
An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines
Fatemeh Bayani, Negin Safaei Hashkavaei, Sareh Arjmand, et al.
Progress in Biophysics and Molecular Biology (2023) Vol. 178, pp. 32-49
Open Access | Times Cited: 40
Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19
Nicolas de Prost, Étienne Audureau, Nicholas Heming, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 55
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses
Aiste Dijokaite-Guraliuc, Raksha Das, Daming Zhou, et al.
Cell Reports (2023) Vol. 42, Iss. 4, pp. 112271-112271
Open Access | Times Cited: 37
Outcome of early treatment of SARS‐CoV‐2 infection in patients with haematological disorders
Małgorzata Mikulska, Diletta Testi, Chiara Russo, et al.
British Journal of Haematology (2023) Vol. 201, Iss. 4, pp. 628-639
Open Access | Times Cited: 30
SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
Shuai Xia, Lijue Wang, Fanke Jiao, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 24
Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses
Chang Yi Wang, Wen‐Jiun Peng, Be-Sheng Kuo, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 4, pp. e1010870-e1010870
Open Access | Times Cited: 24
SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19
Zeinab Mohseni Afshar, Ali Tavakoli Pirzaman, Bardia Karim, et al.
Diagnostics (2023) Vol. 13, Iss. 3, pp. 559-559
Open Access | Times Cited: 23
Multiplexed discrimination of SARS-CoV-2 variants via plasmonic-enhanced fluorescence in a portable and automated device
Ying Liu, Yang Yang, Guanghui Wang, et al.
Nature Biomedical Engineering (2023) Vol. 7, Iss. 12, pp. 1636-1648
Closed Access | Times Cited: 22
Cationic crosslinked carbon dots-adjuvanted intranasal vaccine induces protective immunity against Omicron-included SARS-CoV-2 variants
Lei Hong, Aqu Alu, H. J. Yang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 21
Host range, transmissibility and antigenicity of a pangolin coronavirus
Yixuan J. Hou, S. Chiba, Sarah R. Leist, et al.
Nature Microbiology (2023) Vol. 8, Iss. 10, pp. 1820-1833
Open Access | Times Cited: 21
Favipiravir for treating COVID-19
Pritish John Korula, Hanna Alexander, Jisha Sara John, et al.
Cochrane library (2024) Vol. 2024, Iss. 2
Open Access | Times Cited: 10
Potential immune evasion of the severe acute respiratory syndrome coronavirus 2 Omicron variants
Luyi Chen, Ying He, Hongye Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
SARS-CoV-2—The Role of Natural Immunity: A Narrative Review
Sara Diani, Erika Leonardi, Attilio Cavezzi, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 21, pp. 6272-6272
Open Access | Times Cited: 33
Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice
Alexander Muik, Bonny Gaby Lui, Maren Bacher, et al.
Science Immunology (2022) Vol. 7, Iss. 78
Open Access | Times Cited: 28
SARS-CoV-2 before and after Omicron: two different viruses and two different diseases?
Renata Gili, Roberto Burioni
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 20
Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review
Maryam Arabi, Yousef Al‐Najjar, Omna Sharma, et al.
BMC Infectious Diseases (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 20
Enhanced recombination among Omicron subvariants of SARS‐CoV‐2 contributes to viral immune escape
Rishad Shiraz, Shashank Tripathi
Journal of Medical Virology (2023) Vol. 95, Iss. 2
Closed Access | Times Cited: 18
Modelling how increased Cathepsin B/L and decreased TMPRSS2 usage for cell entry by the SARS-CoV-2 Omicron variant may affect the efficacy and synergy of TMPRSS2 and Cathepsin B/L inhibitors
Pranesh Padmanabhan, Narendra M. Dixit
Journal of Theoretical Biology (2023) Vol. 572, pp. 111568-111568
Open Access | Times Cited: 16
Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5
Hitoshi Kawasuji, Yoshitomo Morinaga, Hideki Tani, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 2
Open Access | Times Cited: 15
Omicron BA.2 breakthrough infection elicits CD8 + T cell responses recognizing the spike of later Omicron subvariants
Sang-Hoon Kim, Jihye Kim, Sungmin Jung, et al.
Science Immunology (2024) Vol. 9, Iss. 91
Closed Access | Times Cited: 5
Next generation sequencing of multiple SARS-CoV-2 infections in the Omicron Era
Marzia Cavalli, Giulia Campoli, Anna Anselmo, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top